These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21226226)

  • 1. [Aldosterone blocker in heart failure: life prolonging even in mild symptoms].
    MMW Fortschr Med; 2010 Dec; 152(48):12-3. PubMed ID: 21226226
    [No Abstract]   [Full Text] [Related]  

  • 2. Aldosterone antagonism in heart failure.
    Richards AM; Nicholls MG
    Lancet; 1999 Sep; 354(9181):789-90. PubMed ID: 10485716
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 4. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
    MMW Fortschr Med; 2005 Jul; 147(27-28):44. PubMed ID: 16041942
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 7. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 8. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone receptor antagonists for heart failure: current status, future indications.
    Pitt B; Rajagopalan S
    Cleve Clin J Med; 2006 Mar; 73(3):257-60, 264-8. PubMed ID: 16548448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Yamamoto T
    Nihon Rinsho; 2007 May; 65 Suppl 5():102-6. PubMed ID: 17571373
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
    Overbeck P
    MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260911
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].
    MMW Fortschr Med; 2005 Dec; 147(48):66-7. PubMed ID: 16392155
    [No Abstract]   [Full Text] [Related]  

  • 16. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; GumuĊ‚ka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure--and an interaction with beta blockade.
    Coats AJ
    Int J Cardiol; 2001 Jan; 77(1):1-4. PubMed ID: 11150619
    [No Abstract]   [Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonists for heart failure.
    Richards AM
    Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.